Orazio Caffo

Summary

Affiliation: S. Maria del Carmine Hospital
Country: Italy

Publications

  1. ncbi request reprint Physical side effects and quality of life during postoperative radiotherapy for uterine cancer. Prospective evaluation by a diary card
    Orazio Caffo
    Department of Medical Oncology, St Chiara Hospital, 38100, Trento, Italy
    Gynecol Oncol 88:270-6. 2003
  2. doi request reprint Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy Electronic address
    Radiother Oncol 121:193-198. 2016
  3. ncbi request reprint Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality?
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d and 8216 Oro 38122 Trento, Italy
    Curr Drug Targets 17:1301-8. 2016
  4. doi request reprint Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy Electronic address
    Eur Urol 68:147-53. 2015
  5. doi request reprint Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy Electronic address
    Urol Oncol 33:265.e15-21. 2015
  6. doi request reprint Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients
    Orazio Caffo
    Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy Electronic address
    Clin Genitourin Cancer 12:312-6. 2014
  7. doi request reprint Biochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancer
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy Electronic address
    Urology 82:1090-3. 2013
  8. pmc Conservative treatment of breast ductal carcinoma in situ: results of an Italian multi-institutional retrospective study
    Cristiana Vidali
    S C Radioterapia Oncologica, Azienda Ospedaliero Universitaria Ospedali Riuniti, Via Pietà 19, 34139, Trieste, Italy
    Radiat Oncol 7:177. 2012
  9. doi request reprint An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment
    Orazio Caffo
    Santa Chiara Hospital, Department of Medical Oncology, Largo Medaglie d Oro, 38100 Trento, Italy
    Expert Opin Drug Metab Toxicol 9:1037-51. 2013
  10. doi request reprint Trimodality treatment in the conservative management of infiltrating bladder cancer: a critical review of the literature
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy
    Crit Rev Oncol Hematol 86:176-90. 2013

Detail Information

Publications51

  1. ncbi request reprint Physical side effects and quality of life during postoperative radiotherapy for uterine cancer. Prospective evaluation by a diary card
    Orazio Caffo
    Department of Medical Oncology, St Chiara Hospital, 38100, Trento, Italy
    Gynecol Oncol 88:270-6. 2003
    ..This prospective study used a diary card to evaluate toxicity and daily quality of life changes in uterine cancer patients given postoperative pelvic radiotherapy...
  2. doi request reprint Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy Electronic address
    Radiother Oncol 121:193-198. 2016
    ..We present a pooled analysis of individual patient data out of published trials with gemcitabine-based chemoradiotherapy for MIBC...
  3. ncbi request reprint Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality?
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d and 8216 Oro 38122 Trento, Italy
    Curr Drug Targets 17:1301-8. 2016
    ....
  4. doi request reprint Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy Electronic address
    Eur Urol 68:147-53. 2015
    ....
  5. doi request reprint Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy Electronic address
    Urol Oncol 33:265.e15-21. 2015
    ..The aim of this observational study was to evaluate the clinical outcomes of a contemporary series of docetaxel-treated patients with mCRPC who were 60 years and younger...
  6. doi request reprint Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients
    Orazio Caffo
    Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy Electronic address
    Clin Genitourin Cancer 12:312-6. 2014
    ..We report the enzalutamide effect on primary prostate tumors, assessed by changes of metabolic tumor activity detected by (18)F-fluorocholine-positron emission tomography/computerized tomography ((18)F-FCH PET/CT)...
  7. doi request reprint Biochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancer
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy Electronic address
    Urology 82:1090-3. 2013
    ..To describe the incidence and clinical relevance of biochemical and objective responses to abiraterone acetate (AA) withdrawal (AAWD) in patients with castration-resistant prostate cancer (CRPC)...
  8. pmc Conservative treatment of breast ductal carcinoma in situ: results of an Italian multi-institutional retrospective study
    Cristiana Vidali
    S C Radioterapia Oncologica, Azienda Ospedaliero Universitaria Ospedali Riuniti, Via Pietà 19, 34139, Trieste, Italy
    Radiat Oncol 7:177. 2012
    ....
  9. doi request reprint An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment
    Orazio Caffo
    Santa Chiara Hospital, Department of Medical Oncology, Largo Medaglie d Oro, 38100 Trento, Italy
    Expert Opin Drug Metab Toxicol 9:1037-51. 2013
    ..As most newly diagnosed patients present distant metastases, chemotherapy is the treatment of choice. Chemotherapy also plays a central role in postoperative and radical treatment in addition to radiotherapy...
  10. doi request reprint Trimodality treatment in the conservative management of infiltrating bladder cancer: a critical review of the literature
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy
    Crit Rev Oncol Hematol 86:176-90. 2013
    ..Conservative management requires the multidisciplinary involvement of different specialties in order to give patients a real alternative to surgical treatment...
  11. doi request reprint Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: results from a phase II study
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy
    Urol Oncol 31:180-6. 2013
    ..Its mechanism of action and toxicity profile make pemetrexed suitable for testing in this setting...
  12. doi request reprint Brain metastases from prostate cancer: an emerging clinical problem with implications for the future therapeutic scenario
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d Oro, 38100 Trento, Italy
    Future Oncol 8:1585-95. 2012
    ..However, this problem may be overcome by new active drugs such as cabazitaxel...
  13. doi request reprint Frequency of brain metastases from prostate cancer: an 18-year single-institution experience
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d Oro, 38100 Trento, Italy
    J Neurooncol 111:163-7. 2013
    ....
  14. doi request reprint Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors
    Orazio Caffo
    Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy
    Urology 79:644-9. 2012
    ....
  15. doi request reprint Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era
    Orazio Caffo
    Department of Medical Oncology, Santa Chiara Hospital, Largo Medaglie d Oro, 38100 Trento, Italy
    J Neurooncol 107:191-6. 2012
    ....
  16. doi request reprint Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial
    Orazio Caffo
    Medical Oncology Department, University of Verona, Verona, Italy
    BJU Int 102:1080-5. 2008
    ..To report the results of a randomized phase II trial of docetaxel with and without estramustine phosphate (EP) in patients with hormone-refractory prostate cancer (HRPC)...
  17. doi request reprint Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy
    BJU Int 108:1825-32. 2011
    ..Our data seem to suggest that patients with a better baseline quality of life (and consequently with fewer symptoms) are more likely to achieve a biochemical response...
  18. doi request reprint Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: Long-term cumulative results of 2 prospective single-institution studies
    Orazio Caffo
    Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy
    Cancer 117:1190-6. 2011
    ..The addition of gemcitabine to cisplatin and radiotherapy may enhance disease control...
  19. doi request reprint Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy
    Cancer Chemother Pharmacol 65:1197-202. 2010
    ....
  20. doi request reprint Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy
    Urol Oncol 28:152-6. 2010
    ..The aim of this study was to evaluate whether the addition of estramustine (E) can overcome DOC resistance...
  21. ncbi request reprint Prospective evaluation of quality of life after interstitial brachytherapy for localized prostate cancer
    Orazio Caffo
    Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy
    Int J Radiat Oncol Biol Phys 66:31-7. 2006
    ..The aim of this prospective study was to assess the impact of IB on the QoL of patients with LPC...
  22. doi request reprint Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer
    Viviana Murgia
    Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy
    Int J Gynecol Cancer 20:953-7. 2010
    ..The aim of this phase 2 trial was to evaluate the tolerability and efficacy of combined gemcitabine (G) and epirubicin (E) as second-line treatment for patients with advanced ovarian cancer...
  23. doi request reprint Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme
    Francesca Maines
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy
    Clin Genitourin Cancer 14:48-55. 2016
    ....
  24. ncbi request reprint Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer
    Orazio Caffo
    Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy
    Int J Radiat Oncol Biol Phys 57:1310-6. 2003
    ....
  25. doi request reprint Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer
    Antonello Veccia
    Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d Oro, 38100 Trento, Italy
    Future Oncol 12:493-502. 2016
    ..To assess clinical outcomes in octogenarians treated with docetaxel (DOC) for metastatic castration-resistant prostate cancer...
  26. ncbi request reprint Pain and quality of life after surgery for breast cancer
    Orazio Caffo
    Department of Medical Oncology, Largo Medaglie d Oro, Santa Chiara Hospital, Trento, Italy
    Breast Cancer Res Treat 80:39-48. 2003
    ..Regardless of the type of operation, BC patients may feel pain even without recurrent disease with poor adjustment in terms of quality of life (QL)...
  27. ncbi request reprint Preliminary results of a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (DOC) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC) (HOPLITE trial)
    Orazio Caffo
    Santa Chiara Hospital, Trento, Italy Santa Maria Degli Angeli General Hospital, Pordenone, Italy Civil Hospital, Verona, Italy Istituti Ospitaleri di Cremona, Cremona, Italy University Hospital of Udine, Udine, Italy Medical Oncology 1, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy Oncologia Medica 1 IOV, Padova, Italy S Maurizio Hospital, Bolzano, Italy Civil Hospital, Thiene, Italy National Cancer Institute, Naples, Italy Azienda ULSS 18 Rovigo, Rovigo, Italy Oncology Unit, Policlinico, Bari, Italy San Bortolo Hospital, Vicenza, Italy Azienda ULSS 13, Mirano, Italy
    J Clin Oncol 30:220. 2012
    ..E is considered synergistic with DOC. Aim of this study was to evaluate in a 2 × 2 factorial design, if I DOC could improve QL compared to C DOC and whether E added to DOC could improve its activity...
  28. doi request reprint Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers
    Francesca Maines
    Medical Oncology, S Chiara Hospital, Largo Medaglie d Oro 1, 38100 Trento, Italy
    Future Oncol 12:333-42. 2016
    ..We prospectively investigated the role of (18)F-choline (FCH)-PET/CT in patients receiving enzalutamide after docetaxel...
  29. ncbi request reprint The role of brachytherapy in the management of oropharyngeal carcinomas: the Trento experience
    Andrea Bolner
    Division of Radiotherapy, Ospedale S Chiara, Trento, Italy
    Tumori 88:137-41. 2002
    ....
  30. doi request reprint Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer
    Vincenza Conteduca
    Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori I R S T IRCCS, Via Piero Maroncelli 40, 47014, Meldola, FC, Italy
    Mol Diagn Ther 20:255-63. 2016
    ..We evaluated the association between PSA changes at 4 weeks and clinical outcome...
  31. pmc Impact of post-implant dosimetric parameters on the quality of life of patients treated with low-dose rate brachytherapy for localised prostate cancer: results of a single-institution study
    Antonello Veccia
    Medical Oncology Unit, Santa Chiara Hospital, Largo Medaglie d Oro 1, 38100, Trento, Italy
    Radiat Oncol 10:130. 2015
    ..To assess the relationship between dosimetric parameters and the quality of life (QL) outcomes of patients with low-intermediate-risk localised prostate cancer (LPC) treated with low-dose-rate brachytherapy (LDR-BT)...
  32. doi request reprint Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy
    BJU Int 115:764-71. 2015
    ..To assess the safety and efficacy of abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated in a compassionate named patient programme (NPP)...
  33. doi request reprint Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy
    Future Oncol 11:965-73. 2015
    ..The intermittent administration of chemotherapy is a means of preserving patients' quality of life (QL). The aim of this study was to verify whether the intermittent administration of docetaxel (DOC) improves the patients' QL...
  34. ncbi request reprint A phase II study of liposomal doxorubicin in recurrent epithelial ovarian carcinoma
    Carmela Arcuri
    Division of Medical Oncology, St Chiara Hospital, Trento, Italy
    Tumori 90:556-61. 2004
    ..We conducted a phase II trial to evaluate the efficacy and safety of liposomal formulation of doxorubicin in recurrent ovarian carcinoma patients...
  35. pmc Splice Variants of Androgen Receptor and Prostate Cancer
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy
    Oncol Rev 10:297. 2016
    ..The aim of this paper is to review the published data concerning the role of androgen receptor splice variants in prostate cancer biology, and their potential use as biomarkers when making therapeutic decisions. ..
  36. pmc Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone
    Cristian Lolli
    Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto di Ricovero e Cura a Carattere Scientifico Meldola, Italy
    Front Pharmacol 7:376. 2016
    ..41, p = 0.068). Conclusion: SII and NLR might represent an early and easy prognostic marker in mCRPC patients treated with abiraterone. Further studies are needed to better define their impact and role in these patients...
  37. doi request reprint Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy
    Future Oncol 10:985-93. 2014
    ..To identify factors predicting primary resistance to new-generation hormonal agents (NHAs), abiraterone acetate and enzalutamide in patients with castration-resistant prostate cancer (CRPC)...
  38. ncbi request reprint High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis
    Mattia Barbareschi
    Department of Pathology, Santa Chiara Hospital, Trento, Italy
    Cancer 98:474-83. 2003
    ..Syndecan-1 is a transmembrane heparan sulphate proteoglycan that is involved in cell-cell adhesion, organization of cell-matrix adhesion, and regulation of growth factor signaling...
  39. pmc Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
    Orazio Caffo
    Medical Oncology Department, Santa Chiara Hospital, Trento, Italy
    Clin Interv Aging 12:19-28. 2017
    ....
  40. doi request reprint Cardiovascular toxicities of systemic treatments of prostate cancer
    Antonello Veccia
    Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d Oro 38100 Trento, Italy
    Nat Rev Urol . 2017
    ..Moreover, closer collaboration between oncologists and cardiologists is essential for the identification and/or management of cardiovascular adverse events in patients with prostate cancer...
  41. doi request reprint Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone
    Vincenza Conteduca
    Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCS, Meldola, Italy
    Prostate 75:1329-38. 2015
    ..Metabolic syndrome (MS) has not yet been studied in castration-resistant prostate cancer (CRPC) men treated with novel hormonal therapies. The study aims to assess the impact of MS on outcome from time starting abiraterone...
  42. doi request reprint Gastrointestinal metastases from prostate cancer: a review of the literature
    Francesca Maines
    Medical Oncology Department, S Chiara Hospital, Largo Medaglie d Oro 1, 38100 Trento, Italy
    Future Oncol 11:691-702. 2015
    ..Its purpose is to increase clinical awareness of the increasing incidence of such GIm, contributing to the early detection, accurate diagnosis and, when feasible, appropriate management...
  43. ncbi request reprint Pain after quadrantectomy and radiotherapy for early-stage breast cancer: incidence, characteristics and influence on quality of life. Results from a retrospective study
    Maurizio Amichetti
    Department of Radiotherapy, St Chiara Hospital, Trento, Italy
    Oncology 65:23-8. 2003
    ..This retrospective study, based on self-completed questionnaires, reports the patients' descriptions of pain and its relationships with QL adjustment after quadrantectomy and radiotherapy for BC...
  44. ncbi request reprint Evaluation of toxicity and quality of life using a diary card during postoperative radiotherapy for rectal cancer
    Orazio Caffo
    Department of Medical Oncology, St Chiara Hospital, Trento, Italy
    Dis Colon Rectum 45:459-65; discussion 465-7. 2002
    ..This prospective study evaluated by means of a diary card the toxicity and daily changes in the quality of life of patients with rectal cancer treated with postoperative pelvic radiotherapy...
  45. pmc Supportive care in patients with advanced non-small-cell lung cancer
    M Di Maio
    National Cancer Institute Clinical Trials Unit, Naples
    Br J Cancer 89:1013-21. 2003
    ..Chemotherapy does not remarkably affect the pattern of SC, except for some drugs against side effects. Elderly patients assume more drugs for concomitant diseases and receive less antiemetics than adults...
  46. ncbi request reprint Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry
    Elena Marangon
    Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milan, Italy
    J Mass Spectrom 43:216-23. 2008
    ..0 microg/ml (22.8 microM). The method was successfully used to study the drug pharmacokinetics in patients with advanced non-small-cell lung cancer in a phase II trial with gemcitabine administered as a fixed dose-rate infusion...
  47. ncbi request reprint Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Thorac Oncol 2:221-9. 2007
    ....
  48. ncbi request reprint [Zoledronic acid and bone pathology in the course of neoplasia. Part I]
    Orazio Caffo
    Divisione di Oncologia Medica, Ospedale Santa Chiara, Trento
    Tumori 91:22-6. 2005
  49. ncbi request reprint [Zoledronic acid and osseous pathologies in the course of neoplasia. Part II]
    Orazio Caffo
    Divisione di Oncologia Medica, Ospedale Santa Chiara, Trento
    Tumori 91:suppl 23-7. 2005
  50. ncbi request reprint Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly s
    Paolo Maione
    S Giuseppe Moscati Hospital, Avellino, Italy
    J Clin Oncol 23:6865-72. 2005
    ..To study the prognostic value for overall survival of baseline assessment of functional status, comorbidity, and quality of life (QoL) in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy...
  51. ncbi request reprint Prognostic value of thymidine phosphorylase expression in breast carcinoma
    Qifeng Yang
    Second Department of Pathology, Wakayama Medical University School of Medicine, Wakayama City, Japan
    Int J Cancer 97:512-7. 2002
    ..Our findings suggest that TP has little effect on tumor angiogenesis of breast carcinoma, whereas it could represent an interesting marker that could predict response to CMF chemotherapy...